DM1 Therapy
Myotonic Dystrophy Type 1
ResearchActive
Key Facts
About Kinea Bio
Kinea Bio is a private, pre-clinical-stage biotech developing innovative gene therapy platforms and programs for neuromuscular diseases (NMDs) with high unmet need. The company has built a multi-faceted technology suite, including SIMPLI-GT™ for large gene delivery, MyoXpress™ for tuned muscle expression, myotropic capsids for targeted delivery, and BioDrone™ for non-immunogenic repeat administration. Backed by respected scientific founders, non-dilutive NIH grants, and foundation investments, Kinea is advancing a pipeline led by programs for Duchenne Muscular Dystrophy (DMD) and dysferlinopathy.
View full company profileTherapeutic Areas
Other Myotonic Dystrophy Type 1 Drugs
| Drug | Company | Phase |
|---|---|---|
| JUV-161 | Juvena Therapeutics | Phase 1 |
| PPR Editor for DM1 | EditForce | Preclinical |
| ENTR-701 | Entrada Therapeutics | Phase 1 |